CT-4201 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder.[1][2][3] It is a prodrug of the tryptamine psychedelic psilocin that is said to have improved pharmacokinetic properties compared to psilocybin, the primary active constituent of psilocybin-containing mushrooms.[1][2][3][4][5] CT-4201 is being developed by CaaMTech.[1][2][3] As of November 2024, it is in the preclinical research stage of development.[1][2]
| Clinical data | |
|---|---|
| Other names | CT4201 |
| Drug class | Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
See also
edit- Substituted tryptamine
- List of investigational hallucinogens and entactogens
- EB-002, MSP-1014, RE-109 (4-GO-DMT)
- Luvesilocin (4-GO-DiPT)
References
edit- 1 2 3 4 "Delving into the Latest Updates on CT-4201 with Synapse". Synapse. 8 May 2025. Retrieved 1 August 2025.
- 1 2 3 4 Haichin M. "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 1 August 2025.
- 1 2 3 "FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment". Sahm. 14 November 2024. Retrieved 1 August 2025.
- ↑ "CaaMTech receives FDA endorsement for psilocin depression drug development". SPEEDA Edge. 14 November 2024. Retrieved 1 August 2025.
- ↑ "CaaMTech Receives Regulatory Validation for Functional Unblinding Strategy in Psilocin Prodrug Trial". MedPath. 15 November 2024. Retrieved 1 August 2025.
 | This hallucinogen-related article is a stub. You can help Wikipedia by adding missing information. |